文献速递妇科母胎医学

CCNE1与BRD4共扩增与高级别浆液性卵巢癌不良预后相关

CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
PubMed 文献 · Gynecol Oncol · 2020-02-07

该研究基于TCGA和TMA数据,评估高级别浆液性卵巢癌(HGSOC)中CCNE1和BRD4共扩增及cyclin E和BRD4高蛋白表达的临床结局。发现8%的HGSOC存在CCNE1和BRD4共扩增,共扩增患者总生存期更差(39.94 vs 48.06个月,p=0.029)。cyclin E高蛋白表达与不良总生存期和铂耐药相关。

要点

  • 8%的HGSOC存在CCNE1和BRD4共扩增,与更差的总生存期相关。
  • cyclin E高蛋白表达与不良总生存期和铂耐药相关,BRD4无此关联。
  • IHC检测cyclin E和BRD4蛋白表达可能作为共扩增的替代标志物。

核心结论

  • HGSOC中CCNE1和BRD4共扩增与不良总生存期相关。
  • cyclin E高蛋白表达与不良总生存期和铂耐药相关。

研究设计与样本

  • 从TCGA提取579例HGSOC的拷贝数扩增数据。
  • 利用TCGA的RPPA数据测定482例HGSOC中cyclin E和BRD4蛋白表达。
  • 在110例HGSOC的组织微阵列(TMA)中通过免疫组化(IHC)评估cyclin E和BRD4蛋白表达。

主要发现

  • 30%的HGSOC存在CCNE1或BRD4扩增,其中8%为两者共扩增。
  • cyclin E和BRD4蛋白表达呈正相关(RPPA r=0.23,p<0.001;IHC r=0.21,p=0.025)。
  • CCNE1和BRD4共扩增患者的中位总生存期为39.94个月,无扩增患者为48.06个月(p=0.029)。

关键数值与推荐

  • CCNE1和BRD4共扩增定义为两个基因同时存在拷贝数扩增。

临床怎么用

  • 对HGSOC患者可考虑检测CCNE1和BRD4共扩增或cyclin E高表达以评估预后。
  • cyclin E高表达可能提示铂耐药风险,需关注化疗敏感性。
  • IHC检测蛋白表达可能作为共扩增的替代方法,但需进一步验证。

局限性

  • 研究为回顾性分析,样本量有限。
  • IHC作为替代标志物的价值需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: High-grade serous ovarian cancer (HGSOC) is the most common and lethal histological subtype of epithelial ovarian cancer. HGSOC with cyclin E1 gene (CCNE1) amplification and bromodomain and extraterminal 4 (BRD4) amplification have been associated with poor outcomes. Our objective was to evaluate clinical outcomes of HGSOC with co-amplification of CCNE1 and BRD4 and high protein expression of cyclin E and BRD4. METHODS: Copy number amplification data were extracted from The Cancer Genome Atlas (TCGA) for 579 HGSOC. Reverse phase protein array (RPPA) TCGA data were used to determine cyclin E and BRD4 protein expression in 482 HGSOC. Cyclin E and BRD4 protein expression by immunohistochemistry (IHC) was evaluated in a tissue microarray (TMA) of 110 HGSOC. Measured clinical outcomes were survival and platinum sensitivity. RESULTS: Of 30% of HGSOC with amplifications in CCNE1 or BRD4, 8% have both CCNE1 and BRD4 amplification. Protein expression of cyclin E and BRD4 are positively correlated, both by RPPA (r = 0.23; p < 0.001) and by IHC (r = 0.21; p = 0.025). Patients with CCNE1 and BRD4 co-amplified HGSOC have worse overall survival than patients without amplifications, 39.94 vs 48.06 months (p = 0.029). High protein expression of cyclin E, but not BRD4, was associated with poor overall survival (HR 1.62, 1.04-2.53, p = 0.033) and platinum resistance (p = 0.016). CONCLUSION: HGSOC with CCNE1 and BRD4 co-amplification are associated with poor overall survival. Further studies are warranted to determine the use of protein expression by IHC as a surrogate marker for CCNE1 and BRD4 co-amplified HGSOC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Petersen S, Wilson AJ, Hirst J, et al. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes. Gynecol Oncol. 2020. PMID: 32044108. doi:10.1016/j.ygyno.2020.01.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。